What is LNTH's 12-month price target and RQD AI Jury consensus?

LNTH's 12-month base price target is $108.44 (range $82.25 to $127.96), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Stock Ratings / Health Care / LNTH

ORKA (53) NEOG (47) CLDX (29) NTLA (25) ⌘ Pro Terminal →

Lantheus Holdings Inc. (LNTH) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell LNTH stock right now?

Lantheus Holdings Inc. (LNTH) currently earns a Roarable Rating of B+ (Buy — BUY) with 76/100 RQD Confidence. High-quality cash engine (61.1% gross margin, 20% return on capital) with steady institutional support.

$100.31 -0.15% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $100.52

Lantheus Holdings Inc. (LNTH) earns a Roarable Rating of B+ (Buy) with 76/100 RQD Confidence. High-quality cash engine (61.1% gross margin, 20% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B+ • BUY Cap $6.56B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LNTH Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LNTH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Lantheus Holdings Inc. (NASDAQ: LNTH) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 76/100 at a spot price of $100.31 (-0.15% 1D, market cap $6.56B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, LNTH ranks #29 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LNTH compare to ORKA and NEOG in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), LNTH carries a Roarable B+ (76/100 RQD), trailing P/E of 28.0x, gross margin of 61.1%, and ROIC of 20.3%. By comparison, ORKA (Oruka Therapeutics Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC -18.8%, cap $6.41B) and NEOG (Neogen Corporation) posts a D grade (47/100 RQD, P/E N/A, ROIC -0.6%, cap $2.58B). Among the 5-stock peer group, LNTH leads on earnings multiple (28.0x) while LNTH leads on capital efficiency (20.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LNTH?

▼

Per LNTH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001521036), Lantheus Holdings Inc. generated $1.54B in revenue (+0.5% YoY), $233.6M in net income, and $320.8M in free cash flow against $2.23B in total assets and $511.9M in total debt. Key quantitative strengths: Strong cash generator (61.1% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $100.52 (+0.21%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 20.8% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 76/100 (B+) historically ranked in the Top 11% of excess returns over the next 90 days (+7.6% avg 90D alpha vs SPY • 70.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B+

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+8.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LNTH)Realized 20D OHLCV Swing Band: ±1.8%

Deterministic 5-Pillar Attribution (76/100 Composite)

🔍 WHY LNTH SCORES 76/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+17/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 20.8% FCF Margin ($320.8M FCF) & 61.1% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+15/20 pts (20% of score)

20D Institutional Volume Accumulation (±1.8% realized swing band)

▼ #1 Drag / Risk Factor: Macro Regime Fit14/20 pts (-6 pt drag)

Macro rate sensitivity & RSI-14 (55.8) create a -6 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$100.00+0.2% Next Q

Q2 (-2Q)

Grade B$100.24-0.1% Next Q

Q3 (-1Q)

Grade B$100.10+0.2% Next Q

Current

Grade B+$100.31+7.6% Hist 90D α

Trajectory: B- (68) → B+ (76)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the LNTH Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 76/100 (B+) score, LNTH faces multiple-compression risk if 28.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 58.6% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($100.25) or 200D SMA ($91.91) invalidates the momentum regime and cuts Target Base ($108.44) toward Bear Floor ($82.25).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LNTH• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LNTH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 76%NO 24%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

55.830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

5.34>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE81% OF RANGE

L: $50$100.31H: $112

1. Money & Cash Health● HEALTHY

Are profits real cash in the bank?

Real cash coming in backs up reported profits (61.1% gross margin and healthy balance-sheet cushion).

Factor Grade: A-RQD 17 / 20

2. Big Money & Insiders● BUYING

Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: BRQD 30 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: BRQD 29 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bullish on LNTH

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (85)

20.3% ROIC with 61.1% gross margin and 4.90% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (75)

Altman-Z 5.34 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BULLISH (73)

30/40 institutional & smart-money positioning score with 14/20 macro alignment.

Bull Case: Why Buyers Like LNTH

✓Strong cash generator (61.1% gross margin)—profits are backed by real money, not accounting tricks.
✓Big institutional funds and options desks are actively positioning on the bullish side.
✓Company leadership has skin in the game with net positive insider conviction.

Bear Case: What Could Go Wrong

!Broader market pullbacks can still drag down strong stocks in the short run.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (LNTH Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LNTH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +14.27%⚡ TESTING RESISTANCE

2026-11-03O $100.3H $100.5L $100.3C $100.3VOL 476.3K

RES: $100.4SUP: $99.79SMA50: $100.3SMA200: $91.91

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LNTH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LNTH Butterfly Map → + Track LNTH →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

21.4%/yr Implied 5Y Growth

vs. +0.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LNTH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LNTH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LNTH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LNTH)

Health Care Rank #29 of 1015 ⚔️ ORKA vs LNTH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LNTH vs. ORKA, NEOG, CLDX, NTLA)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Lantheus Holdings Inc. (LNTH) ranks #29 by composite RQD confidence (76/100, grade B+) and #136 by equity capitalization ($6.56B). Within this direct 5-issuer industry benchmark cohort, LNTH leads on earnings valuation at 28.0x trailing P/E, while LNTH leads on capital efficiency and profitability with 20.3% ROIC and 61.1% gross margin. LNTH currently leads its immediate peer cohort in composite quantitative strength at 76/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LNTH ACTIVE Lantheus Holdings Inc.	B+	76/100	28.0x	61.1%	20.3%	-0.15%	$6.56B	Benchmark Subject
ORKA Oruka Therapeutics Inc.	D+	53/100	—	—	-18.8%	-1.49%	$6.41B	/orka-vs-lnth →
NEOG Neogen Corporation	D	47/100	—	46.9%	-0.6%	0.00%	$2.58B	/neog-vs-lnth →
CLDX Celldex Therapeutics Inc.	E	29/100	—	87.1%	-35.0%	-3.52%	$2.36B	/cldx-vs-lnth →
NTLA Intellia Therapeutics Inc.	E	25/100	—	—	-35.0%	-6.50%	$1.75B	/ntla-vs-lnth →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001521036 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lantheus Holdings Inc. (LNTH) reported GAAP revenue of $1.54B (+0.5% vs. FY2024 revenue of $1.53B , and +18.9% cumulative change since FY2023) , GAAP net income of $233.6M, operating cash flow of $390.1M, and free cash flow of $320.8M (-32.6% YoY). On the balance sheet, LNTH closed FY2025 with $2.23B in total assets against $511.9M in total debt (Altman Z-Score: 5.34, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.54B	$233.6M	$390.1M	$320.8M	$2.23B	$511.9M
FY2024 (FY)	2024-12-31	$1.53B	$312.4M	$544.8M	$475.7M	$1.98B	$401.5M
FY2023 (FY)	2023-12-31	$1.30B	$326.7M	$305.3M	$246.9M	$3.60B	$842.7M

3. LNTH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LNTH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does LNTH compare to ORKA and NEOG in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for LNTH?

Where is LNTH trading relative to its 50-day, 200-day, and 52-week technical levels?

LNTH last traded at $100.31 (-0.15% on volume of 931,882 shares), positioning the stock +0.06% above its 50-day simple moving average ($100.25) and +9.14% above its 200-day simple moving average ($91.91). Across its 52-week range of $50.15 to $111.86, LNTH sits at the 81.3% percentile with a 14-day RSI of 55.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±1.8% ($98.50 to $102.12).

Direct Sub-Reports: LNTH RQD Cockpit LNTH 12M Forecast LNTH Earnings & Move LNTH Dividends & DRIP LNTH Insiders & 13F LNTH Whale Options LNTH Profit Sankey LNTH News & Why

ROARABLE RATING BRIEF • RQD 76/100 (B+) ✓ SEC XBRL & RQD VERIFIED

LNTH — Lantheus Holdings Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Lantheus Holdings Inc. (LNTH) earns a live Roarable RQD composite score of 76/100, corresponding to a B+ letter grade (Roarable Buy) at a spot price of $100.31 (-0.15% 1D, market capitalization $6.56B).

Fundamental Cash Engine (17/20): Anchored by return on invested capital (ROIC) of 20.3%, gross margin of 61.1%, operating margin of 20.2%, and free cash flow yield of 4.90%.
Whale 13F & Options Flow (15/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (14/20) + Forensic Balance Sheet (15/20): Incorporates a 0.88x equity beta, Altman Z-Score of 5.34, Piotroski F-Score of 7/9, and Debt/Equity of 0.44x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Lantheus Holdings Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry..5B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Lantheus Holdings Inc. (LNTH) reported $1.54B in annual revenue (up from $1.53B in FY2024, +0.5% YoY) and $233.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.30B revenue, $326.7M net income) through FY2025, LNTH scaled operating cash flow to $390.1M and free cash flow to $320.8M, backed by $2.23B in total assets against $511.9M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (B+ • RQD 76/100): Strong cash generator (61.1% gross margin)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 17/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $50.15 – $111.86 52-week range.
🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 28.0x trailing P/E and 18.0x EV/EBITDA against 20.2% operating margins and a 0.88x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), LNTH carries a macro regime beta of 0.88 and gross margin of 61.1%.

Key Question #1: Can LNTH sustain or expand its 20.2% operating margin and 20.3% ROIC against Biotechnology: In Vitro & In Vivo Diagnostic Substances peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $1.54B and free cash flow of $320.8M, how will capital allocation balance growth reinvestment against $511.9M in total debt?
Key Question #3: How sensitive is LNTH's 26.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.88x)?

LNTH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Lantheus Holdings Inc. (LNTH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LNTH Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 22h ago

ETFs Are Selling Lantheus (LNTH) on Oct. 19

Yahoo Finance report covering Lantheus Holdings Inc. (LNTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stocktwits • 1d ago

LNTH Stock Drops After-Hours As Curium's $7B Offer Comes In Below Market Value

Stocktwits report covering Lantheus Holdings Inc. (LNTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockInvest.us • 1d ago

Lantheus Holdings Stock Price Forecast. Should You Buy LNTH?

StockInvest.us report covering Lantheus Holdings Inc. (LNTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Zacks Investment Research • 1d ago

Should I buy Lantheus (LNTH)

Zacks Investment Research report covering Lantheus Holdings Inc. (LNTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

ETFs Are Net Sellers of Lantheus (LNTH) on Oct. 22

Yahoo Finance report covering Lantheus Holdings Inc. (LNTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Vanguard amends its Lantheus (LNTH) stake report, with sole voting power over 60,159 shares.

Stock Titan report covering Lantheus Holdings Inc. (LNTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Lantheus Holdings (LNTH) Holds the $100 Line as Shares Edge 0.08% Lower - Jelly Roll Trade

https://www.siam.in/ report covering Lantheus Holdings Inc. (LNTH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 1d ago

Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer’s Disease Annual Meeting

BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease t

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LNTH Bull vs. Bear Conversation Board — What's Your Call at $100.31?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LNTH 🐻 33% BEARISH CONVICTION

TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $130.60 (+30.0%)

📌 Pinned Debate

A 20.3% ROIC, a 5.34 Altman Z-Score, and a 0.44 Debt/Equity ratio point to a high-return, low-leverage business.

Here is why I am bullish on LNTH here at $100.46: A 20.3% ROIC, a 5.34 Altman Z-Score, and a 0.44 Debt/Equity ratio point to a high-return, low-leverage business.. Compare LNTH's 20.2% operating margin and 20.3% ROIC against the rest of Biotechnology: In Vitro & In Vivo Diagnostic Substances. As long as cash conversion holds up, dips toward $95.44 are getting bought.

VolSurface_Trader 🐂 BULL

@RedlineAuditor Shorting a 15/20 institutional whale-flow stock at $100.46 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $79.36 (-21.0%)

Spot @ $100.46

Revenue grew from $1.30B to $1.54B while net income fell from $326.7M to $233.6M and cash dropped from $912.8M to $359.1M.

Revenue grew from $1.30B to $1.54B while net income fell from $326.7M to $233.6M and cash dropped from $912.8M to $359.1M.. Look at the math on LNTH: paying 28.0x trailing P/E for 20.3% ROIC and 20.2% operating margins leaves zero margin of safety if Biotechnology: In Vitro & In Vivo Diagnostic Substances demand softens. I'd wait for a retest of $88.40 before getting long.